Who owns the VIDEX QD trademark?

The VIDEX QD trademark is owned by BRISTOL-MYERS SQUIBB COMPANY.

What class is the VIDEX QD trademark registered in?

The VIDEX QD trademark is registered in Class 005 (Pharmaceuticals, medical & veterinary preparations).

What is the serial number for VIDEX QD?

The USPTO serial number for VIDEX QD is 75629288.

What is the registration number for VIDEX QD?

VIDEX QD is registered under USPTO registration number 0.

Sealvo

Home Search: VIDEX QDVIDEX QD #75629288

Back

Updated Oct 12, 2026·38 searches this week

View on USPTO TSDR Find similar marks

VID

USPTO Trademark Record

ABANDONED

VIDEX QD

SN 75629288·Reg 0·Filed Jan 28, 1999

Owner BRISTOL-MYERS SQUIBB COMPANY

Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary purposes, food for babies; dietary supplements for human beings and animals; adhesive plasters, materials for dressings; material for filling teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.

VIDEX QD (Serial No. 75629288), Registration No. 0, is a abandoned US trademark filed on Jan 28, 1999 by BRISTOL-MYERS SQUIBB COMPANY. This trademark covers Class 005 (Pharmaceuticals, medical & veterinary preparations).

Mark Intelligence

VIDEX QD (Reg. #0) is an abandoned US trademark that was filed in 1999 but has since been abandoned. The mark covers Class 005 (Pharmaceuticals, medical & veterinary preparations). Goods and services include Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and subs.... The mark faced 1 opposition proceeding during prosecution.

FILED

Jan 28, 1999

SERIAL

75629288

REG#

Filing Information

StatusABANDONED

Filing DateJan 28, 1999

Serial Number75629288

Registration No.0

Status DateFeb 02, 2001

Published for OppositionNov 09, 1999

Mark TypeTypeset (words/letters/numbers)

Filing Basis & Declarations

Standard Characters ClaimedTrademark

Full Goods & Services

CLASSES

OFFICE

USPTO

COUNTRY

Class 005Pharmaceuticals, medical & veterinary preparations

US codes: 006, 018, 044, 046, 051, 052

This description is as filed with the USPTO and defines the scope of trademark protection.

Run a conflict check

Search by serial number, mark name, or logo. See conflicting marks ranked by risk with clear explanations of what contributed.

Run conflict check

Status History

10 events

ABANDONMENT - NO USE STATEMENT FILED

Jun 06, 2001

ABANDONMENT - NO USE STATEMENT FILED

SOU EXTENSION 1 GRANTED

Aug 02, 2000

SOU EXTENSION 1 GRANTED

SOU EXTENSION 1 FILED

Jun 20, 2000

SOU EXTENSION 1 FILED

NOA MAILED - SOU REQUIRED FROM APPLICANT

Feb 01, 2000

NOA MAILED - SOU REQUIRED FROM APPLICANT

PUBLISHED FOR OPPOSITION

Nov 09, 1999

PUBLISHED FOR OPPOSITION

NOTICE OF PUBLICATION

Oct 08, 1999

NOTICE OF PUBLICATION

APPROVED FOR PUB - PRINCIPAL REGISTER

Jul 23, 1999

APPROVED FOR PUB - PRINCIPAL REGISTER

EXAMINER'S AMENDMENT MAILED

Jul 15, 1999

EXAMINER'S AMENDMENT MAILED

ASSIGNED TO EXAMINER

Jul 14, 1999

ASSIGNED TO EXAMINER

Jul 14, 1999

ASSIGNED TO EXAMINER

Other Marks by BRISTOL-MYERS SQUIBB COMPANY

Additional USPTO filings from the same owner.

TOM

TOMORROW'S INNOVATORS IN SCIENCE, TECHNOLOGY, ENGINEERING AND MATH

98978549

Bristol-Myers Squibb Company

REGISTERED

EMP

EMPLICITI

99424859

BRISTOL-MYERS SQUIBB COMPANY

REGISTERED

SPR

SPRYCEL

78140234

Bristol-Myers Squibb Company

REGISTERED

OPD

OPDIVO

86174642

Bristol-Myers Squibb Company

REGISTERED

Other Marks in Class 005 — Pharmaceuticals, medical & veterinary preparations

Recently filed and registered marks in the same international class.

VID

VIDEX

73825741

BRISTOL-MYERS SQUIBB COMPANY

REGISTERED

VID

VIDEX EC

78223415

Bristol-Myers Squibb Company

REGISTERED

PRO

PRORENAL QD

77605181

Nephroceuticals, LLC

REGISTERED

PRO

PRORENAL QD

77647725

NEPHROCEUTICALS, LLC

REGISTERED

Other Marks by Nadine P. Flynn

Additional USPTO filings handled by the same attorney of record.

IXE

IXEMPLE A PHASE III OPEN LABEL, RANDOMIZED, 2 ARM STUDY OF IXABEPILONE ADMINISTERED EVERY 21 DAYS VERSUS PACLITAXEL OR DOXORUBICIN ADMINISTERED EVERY 21 DAYS IN WOMEN WITH ADVANCED ENDOMETRIAL CANCER WHO HAVE PREVIOUSLY BEEN TREATED WITH CHEMOTHERAPY

77775355

OTHERS

IXA

IXAMPLE A PHASE III OPEN LABEL, RANDOMIZED, 2 ARM STUDY OF IXABEPILONE ADMINISTERED EVERY 21 DAYS VERSUS PACLITAXEL OR DOXORUBICIN ADMINISTERED EVERY 21 DAYS IN WOMEN WITH ADVANCED ENDOMETRIAL CANCER WHO HAVE PREVIOUSLY BEEN TREATED WITH CHEMOTHERAPY

77775341

OTHERS

IXA